BG107613A - Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена - Google Patents

Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена Download PDF

Info

Publication number
BG107613A
BG107613A BG107613A BG10761303A BG107613A BG 107613 A BG107613 A BG 107613A BG 107613 A BG107613 A BG 107613A BG 10761303 A BG10761303 A BG 10761303A BG 107613 A BG107613 A BG 107613A
Authority
BG
Bulgaria
Prior art keywords
region
polypeptide
tnf
seq
amino acid
Prior art date
Application number
BG107613A
Other languages
Bulgarian (bg)
English (en)
Inventor
Thomas Wust
Dieter Moosmayer
Matthias Grell
Peter Scheurich
Original Assignee
Universitat Stuttgart
Pfizenmaier Klaus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Stuttgart, Pfizenmaier Klaus filed Critical Universitat Stuttgart
Publication of BG107613A publication Critical patent/BG107613A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BG107613A 2000-09-15 2003-03-06 Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена BG107613A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045592A DE10045592A1 (de) 2000-09-15 2000-09-15 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
PCT/EP2001/010730 WO2002022833A1 (de) 2000-09-15 2001-09-17 Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug

Publications (1)

Publication Number Publication Date
BG107613A true BG107613A (bg) 2003-12-31

Family

ID=7656260

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107613A BG107613A (bg) 2000-09-15 2003-03-06 Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена

Country Status (22)

Country Link
US (1) US20040053829A1 (et)
EP (1) EP1317556A1 (et)
JP (1) JP2004508828A (et)
KR (1) KR20030048041A (et)
CN (1) CN1214115C (et)
AU (1) AU2001293819A1 (et)
BG (1) BG107613A (et)
BR (1) BR0113928A (et)
CA (1) CA2422759A1 (et)
DE (1) DE10045592A1 (et)
EE (1) EE200300100A (et)
HR (1) HRP20030192A2 (et)
HU (1) HUP0301693A3 (et)
IL (1) IL154185A0 (et)
MX (1) MXPA03002229A (et)
NO (1) NO20031185L (et)
PL (1) PL360540A1 (et)
RU (1) RU2003106429A (et)
SK (1) SK2812003A3 (et)
WO (1) WO2002022833A1 (et)
YU (1) YU18903A (et)
ZA (1) ZA200302008B (et)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239403A1 (en) * 2000-12-01 2002-06-11 The Johns Hopkins University Tissue specific prodrugs
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) * 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
CA2697032C (en) * 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
US20100189651A1 (en) * 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5861223B2 (ja) * 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
WO2019173832A2 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
CN120463822A (zh) * 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
KR20220020879A (ko) * 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
US20220289822A1 (en) * 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US20220356221A1 (en) * 2019-09-28 2022-11-10 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
WO2021142471A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (de) * 1999-01-11 2000-07-13 Falkenberg Frank W Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren

Also Published As

Publication number Publication date
HRP20030192A2 (en) 2005-10-31
KR20030048041A (ko) 2003-06-18
NO20031185D0 (no) 2003-03-14
JP2004508828A (ja) 2004-03-25
SK2812003A3 (en) 2003-11-04
EE200300100A (et) 2005-02-15
DE10045592A1 (de) 2002-03-28
WO2002022833A1 (de) 2002-03-21
CN1458977A (zh) 2003-11-26
MXPA03002229A (es) 2005-06-20
US20040053829A1 (en) 2004-03-18
AU2001293819A1 (en) 2002-03-26
HUP0301693A3 (en) 2005-11-28
EP1317556A1 (de) 2003-06-11
RU2003106429A (ru) 2004-08-27
IL154185A0 (en) 2003-07-31
HUP0301693A2 (hu) 2003-08-28
NO20031185L (no) 2003-05-05
ZA200302008B (en) 2004-06-25
BR0113928A (pt) 2003-07-22
YU18903A (sh) 2006-05-25
PL360540A1 (en) 2004-09-06
CA2422759A1 (en) 2003-03-17
CN1214115C (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
BG107613A (bg) Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена
JP7820448B2 (ja) 新規のサイトカインプロドラッグ
CA2095836C (en) Cytokine immunoconjugates
US9775913B2 (en) Method of site specific activation of an antibody by a protease
EP1891102B1 (en) Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US8048985B2 (en) Diphtheria toxin variant
EP0706799B1 (en) Immunoconjugates II
AU2001275246B2 (en) T cell receptor fusions and conjugates and methods of use thereof
JP2019163258A (ja) 受容体媒介クリアランスが減少した、生理活性ポリペプチド単量体と免疫グロブリンFc断片との結合体及びその製造方法
AU2006320858A1 (en) Methods for production of receptor and ligand isoforms
US20120189634A1 (en) Taci as an anti-tumor agent
CN115175917A (zh) 药物缀合物及其应用
NZ521629A (en) TACI as an anti-tumor agent
AU2001253920A1 (en) Use of taci as an anti-tumor agent
EP0467536A2 (en) Method of treating bladder cancer cells
WO2007014744A2 (en) C-terminal tnf-family ligand (ctl) -prodrug
Wüest et al. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor
CN101914161A (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
WO2019176866A1 (ja) ウテログロビンを構造基盤とする二重特異性ポリペプチド
CN117683140A (zh) 肿瘤靶向的以白介素2为活性成分的融合蛋白型药物前体
NZ710925B2 (en) Chimeric antigen receptor and methods of use thereof
HK1113579B (en) Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12
MXPA01001970A (en) Expression and export of angiostatin and endostatin as immunofusis